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ABSTRACT
Mdc1 is a large modular phosphoprotein scaffold
that maintains signaling and repair complexes
at double-stranded DNA break sites. Mdc1 is
anchored to damaged chromatin through inter-
action of its C-terminal BRCT-repeat domain with
the tail of cH2AX following DNA damage, but the role
of the N-terminal forkhead-associated (FHA) domain
remains unclear.We show that amajor binding target
of the Mdc1 FHA domain is a previously unidentified
DNA damage and ATM-dependent phosphorylation
site near the N-terminus of Mdc1 itself. Binding to
this motif stabilizes a weak self-association of the
FHA domain to form a tight dimer. X-ray structures of
free and complexed Mdc1 FHA domain reveal a
‘head-to-tail’ dimerization mechanism that is closely
related to that seen inpre-activated formsof theChk2
DNA damage kinase, and which both positively and
negatively influences Mdc1 FHA domain-mediated
interactions in human cells prior to and following
DNA damage.
INTRODUCTION
Genomic integrity is constantly challenged by the effects
of DNA-damaging agents. Double-stranded DNA breaks
(DSBs) are considered to be the most genotoxic lesions
since incorrect repair can lead to chromosome breaks
and other aberrations that are characteristic of and
which may lead to cancer. DSBs initiate a program of
cellular responses involving activation of cell-cycle check-
points and deployment of the repair machinery. Central to
DNA damage response (DDR) regulation is a protein
kinase cascade involving ataxia telangiectasia-mutated
kinase (ATM), which acts as sensor of DSBs, initiating
damage signals that are propagated through phos-
phorylation of checkpoint kinases and other diverse
downstream targets (1). Many of these phosphorylation
events are now known to initiate protein–protein inter-
actions mediated by phosphoserine/threonine-speciﬁc
binding domains, most commonly forkhead-associated
(FHA) and Brca1 C-terminal (BRCT) modules (2),
providing for highly regulated, physical links between
DDR components.
Mediator of the DNA damage Checkpoint-1 (Mdc1) is
a modular, 2089 amino acid protein originally identiﬁed as
an essential factor for establishment of DNA damage
checkpoints (3–6). It functions as an assembly platform
for the localization and maintenance of signaling and
repair factors at and around DSB sites (7). As such,
Mdc1 is a founding member of a class of large scaffold-
ing/adaptor proteins known as ‘mediators’ that includes
proteins such as human Brca1, 53BP1 and yeast Rad9 and
Crb2. While all of these molecules contain two or more
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copies of BRCT-repeat motifs, Mdc1 uniquely contains an
additional FHA domain at its N-terminus.
Functionally, the C-terminal BRCT-repeats tether
Mdc1 to regions of DNA damage by virtue of their
speciﬁc binding to ATM-phosphorylated H2AX (known
as gH2AX), a variant histone H2A, which acts as the
primary marker of damaged chromatin in all eukaryotic
cells (8). In contrast, the function of the FHA domain is
less clear but has been suggested to include interaction
with ATM itself (9,10), Chk2 (3), components of the
Mre11/Rad50/Nbs1 (MRN) complex (5,11) and other
repair proteins such as Rad51 (12). We now show that
the Mdc1 FHA domain mediates an inter-molecular inter-
action with a previously uncharacterized ATM phosphor-
ylation site located within its own N-terminal region,
revealing a role for DNA damage-inducible Mdc1 dimer-
ization in the cellular response to double-stranded DNA
breaks with a more general signiﬁcance for understanding
regulatory mechanisms that underpin FHA domain
function in other signaling contexts.
MATERIALS AND METHODS
Plasmids
Human Mdc1-GST constructs were previously described
(13) Human Mdc1 (800) comprising amino acids 1–800
was generated by PCR and C-terminally tagged with
HA/FLAG and Myc, respectively, and cloned into
pcDNA3.1 (+) mammalian expression vector (Invitrogen).
The Mdc1 FHA domain-containing fragment (amino
acids 1–154) was ampliﬁed by PCR and cloned into a
modiﬁed pEYFP-nuc vector (Clontech), in which two
tetracycline-repressor binding elements were inserted
between promotor and coding sequences to generate
an inducible expression cassette (8). Point mutations
were introduced by PCR-based methods or using the
QuikChange Site-Directed Mutagenesis kit (Stratagene).
Protein expression and puriﬁcation
DNA fragments encoding human Mdc1 residues 1–138,
19–138 or 27–138 were ampliﬁed from a Mdc1 cDNA
clone and ligated into BamH1/Xho1 digested pGEX-
6P1. GST-fusion proteins were afﬁnity puriﬁed on
glutathione-4B resin (Amersham) and cleaved from the
afﬁnity resin with rhinovirus 3C protease overnight at
4C. Cleaved Mdc1 fragments were further puriﬁed by
gel-ﬁltration chromatography on Superdex 75.
Structure solution and reﬁnement
The structure of the selenomethionine peptide complex
was solved by the single-wavelength anomalous diffrac-
tion (SAD) method using data collected on beamline
10.1 at the SRS Daresbury, UK. Four selenium sites
were located and phases reﬁned by SOLVE/RESOLVE
(14). The resulting map was readily interpretable
allowing an essentially complete model for the two
complexes in the asymmetric unit. The resulting FHA
domain structure was then used to solve the non-
complexed crystal form by molecular replacement using
PHASER (15). Model-building was carried out with
‘Coot’ (16) and both structures were reﬁned using
REFMAC5 (17).
Cell culture and gene transfer
Mdc1/ and Mdc1+/+ MEFs were gifts from J. Chen
(University of Texas MD Anderson Cancer Center,
Houston, TX, USA). U2OS, HEK 293T and MEFs
were grown in D-MEM (Invitrogen) supplemented with
10% FCS (Gibco) and streptomycin/penicillin (100U/ml,
Gibco). Transfection of plasmids was done using either
FuGene 6 (Roche) or calcium phosphate. U2OS-TetOn
cells stably expressing the tetracycline repressor were
generated by transfection of EYFP-tagged Mdc1-FHA
domain following selection in G418-containing medium
(Calbiochem). The siRNA oligonucleotides against en-
dogenous human Mdc1 were purchased from Ambion
(siRNA ID: 21738) containing the following sequence:
sense 50-GGAUCACACAAAGAUUAGAtt and anti-
sense 50-UCUAAUCUUUGUGUGAUCCtt. SiRNA
transfections were performed using Lipofectamine
RNAiMAX (Invitrogen) according the manufacturer’s
protocol. DNA damage was induced in a Faxitron
X-ray cabinet at 5–10Gy/min. or by means of single-cell
laser microirradiation (see below).
Antibodies
The mouse monoclonal gH2AX antibody was obtained
from Millipore and the rabbit polyclonal c-Myc
antibody (sc-789) from Santa Cruz Biotechnology. The
rabbit polyclonal FLAG antibody and the anti-FLAG
M2 afﬁnity gel, used for co-immunoprecipitation, were
purchased from Sigma. Rabbit polyclonal Mdc1(889)
and sheep polyclonal Mdc1(3835) antibodies were raised
against Mdc1-FHA-GST as described previously (5). The
phosphospeciﬁc antibody Mdc1 ‘pT4’ was raised in rabbit
against the phosphopeptide MED(pT)QAIDWDVC and
afﬁnity puriEed using the phosphorylated and non-
phosphorylated peptide (Eurogentec). Rabbit polyclonal
ATM antiserum for ATM immunoprecipitation was a
kind gift from Graeme Smith (KuDOS Pharmaceuticals,
Cambridge, UK).
Expressed protein ligation
Puriﬁed Mdc1 1–158 was digested with trypsin (Promega)
at a ratio of 1:250 w/w enzyme:substrate to yield a
112 residue fragment (26–138) containing the FHA
domain and part of the preceding linker with Cys-26 at
its N-terminus. Synthesis of a C-terminally protected
pThr-4 peptide (MEDpTQAIDWDVEEEEETEQSSESL
R-SBn) and in vitro ligation to the Mdc1 26–138 fragments
were carried in 200mM phosphate buffer pH 8.0, 150mM
NaCl, 10mM TCEP, 2% w/v 2-mercaptoethanesulphonic
acid overnight at room temperature.
Pulldown of Mdc1–FHA interaction partners
Stable, Doxocycline-inducible cell lines were generated
by co-transfecting U2OS cells with pcDNA6/TO express-
ing the Tet-repressor and pcDNA5/TO expressing a
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C-terminally Strep-tagged Mdc1-FHA domain (amino
acids 1–154). Stable clones were selected with
Hygromycin B (Sigma) and Blasticidin (Invitrogen) and
subsequently cultured in DMEM supplemented with
10% dialyzed FBS (Invitrogen) and either L-lysine
(Lys0) and L-arginine (Arg0), L-lysine 4,4,5,5-D4 (Lys4)
and L-arginine–U-13C6 (Arg6) or L-lysine–U-
13C6-
15N2
(Lys8) and L-arginine–U-13C6-
15N4 (Arg10) (Cambridge
Isotope Laboratory) as described previously (18).
Following 16 h of doxocyclin induction and IR treatment
(10Gy for 30min), cells were lysed in buffer containing
50mM Tris–HCl (pH 7.5), 150mM NaCl, 1mM EDTA,
1mM MgCl2,1% NP-40, 2mM Na-orthovanadate, 5mM
NaF, 5mM glycero-2-phosphate and protease inhibitors
(CompleteTM tablets, Roche). Equal protein amounts
were incubated with Strep-Tactin Sepharose (IBA
BioTAGnology) and bound complexes were eluated
in Laemmli sample buffer, combined and resolved on
4–20% SDS–PAGE. The CB-stained gel was cut into
slices, proteins were digested with trypsin and loaded on
to C18 stage tips prior to mass spectrometric analysis.
Mass spectrometric analysis
MS analysis was performed on a nanoscale HPLC system
(Easy-nLC from Proxeon) connected to a hybrid LTQ
Orbitrap Velos mass spectrometer (Thermo Scientiﬁc).
Peptides were separated over a 110min linear gradient
from 5% to 40% acetonitrile in 0.5% acetic acid with a
ﬂow rate of 250 nl/min. Survey full scan MS spectra were
acquired from m/z 300 to 1700 in the Orbitrap detector
with a resolution of R=30000 followed by isolation and
fragmentation of the 10 most intense ions using HCD
(higher energy collisional activation dissociation) at reso-
lution R=7500 (19). Raw data ﬁles were processed with
the MaxQuant software suite (www.maxquant.org).
Proteins and peptides were identiﬁed by Mascot data-
base search against a target/decoy (forward and reversed)
version of the IPI human database 3.80 with a false
discovery rate (FDR) for peptides and proteins of <1%.
RESULTS
Mdc1 Thr-4 is a novel site of ATM phosphorylation
in vitro and in vivo
Mdc1 contains many potential PI3 kinase-like protein
kinase (PIKK) target sites (S/TQ-motives) throughout its
open reading frame and early studies have shown that
upon genotoxic stress, Mdc1 is rapidly phosphorylated
in a PIKK-dependent manner (3–5). However, only few
of these potential PIKK target sites are conserved and the
extent and physiological relevance of PIKK-dependent
Mdc1 phosphorylation are largely unknown. In order to
identify bona ﬁde PIKK target sites in Mdc1, we generated
eight overlapping fragments of the human Mdc1 cDNA
and expressed them in E. coli as GST-fusion proteins as
described previously (13) (Figure 1a). All but one
fragment (M-6) comprising the Mdc1 PST-repeat region,
expressed well and could be puriﬁed (Figure 1a, upper
panel). These fragments were then phosphorylated
in vitro using immunoprecipitated human ATM (20).
Surprisingly, ATM only phosphorylated fragment M-1
(amino acids 1–124) and fragment M-4 (amino acids
531–770) (Figure 1a, lower panel). Fragment M-4
features a cluster of four conserved ‘T-Q-X-F’ motifs
that constitute binding sites for the FHA domain of the
ubiquitin ligase RNF8 following phosphorylation by
ATM (21–23). Fragment M-1 contains two conserved
TQ motifs: one at the very N-terminus of Mdc1 (Thr-4/
Gln-5) and one within the FHA domain (Thr-98/Gln-99).
Thr-4 appears to be the major site of ATM phosphoryl-
ation since a deletion mutant of M-1 lacking the ﬁrst 18
amino acids was not phosphorylated by ATM in vitro
(Supplementary Figure S1), and a point mutation
altering Thr-4 to Ala (T4A) resulted in a protein that
could no longer be phosphorylated by ATM in vitro
(Figure 1b).
In order to investigate Thr-4 phosphorylation in vivo,
we raised a phosphor-speciﬁc antibody (pT4) directed
against a pThr-4 peptide derived from the Mdc1
N-terminus. The antibody recognized the in vitro
phosphorylated M-1 fragment and cross-reacted only min-
imally with the unphosphorylated form of M-1 and a T4A
mutant M-1 fragment (Figure 1b, third panel). Moreover,
the antibody did not recognize the repeating TQxF motifs
within fragment M-4 (Supplementary Figure S2) either
before or after ATM phosphorylation, indicating clear
speciﬁcity for the pThr-4 site. We then exposed U2OS
cells to various doses of IR and analyzed total cell
extracts by immunoblotting with the pT4 antibody. The
antibody cross-reacted with several proteins in total cell
extracts, but one band (migrating at 250 kDa) appeared
only in extracts derived from cells that had been treated
with IR (Supplementary Figure S3). The intensity of this
band increased with increasing dose of IR (Figure 1c, left).
Stripping and reprobing the blot with an antibody against
human Mdc1 revealed that the protein recognized by the
pT4 antisera overlapped with at least one of the Mdc1
isoforms. Time course analysis showed that 1 h post irradi-
ation, phosphorylation levels were maximal and then
slowly decreased to background levels after 21 h
(Figure 1c, right panels). Moreover, in cells expressing a
tagged T4A-mutated version of the Mdc1 N-terminus,
only a very weak signal was detectable by the pT4
antibody, while the wild-type protein was readily
detected (Supplementary Figure S4).
To exclude the possibility that the pT4 antibody
cross-reacted with another protein phosphorylated in
response to IR, we subjected Mdc1/ mouse embryonic
ﬁbroblasts and control (Mdc1+/+) cells to various doses of
IR and analyzed total cell extracts by immunoblotting
using the pT4 antibody. In extracts prepared from
irradiated Mdc1+/+ MEFs, a clear signal appeared on
polyacrylamide gels at the position where mouse Mdc1
would be expected. No such signal was detected in
extracts derived from irradiated Mdc1/ cells, indicating
that the protein recognized by the pT4 antibody indeed
corresponds to Mdc1 (Figure 1d).
Mdc1 phosphorylation in response to IR is ATM de-
pendent (3–5). Consistent with this, no Mdc1 signal was
detected by the pT4 antibody in extracts from irradiated
cells that had been pre-treated with a speciﬁc ATM
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Figure 1. ATM targets Mdc1 on a conserved threonine residue at its N-terminus. (a) In vitro ATM kinase assay of recombinant Mdc1 fragments.
Top: Schematic representation of Mdc1’s domain architecture and of the GST-fusion fragments derived from its cDNA. Bottom: (Upper panel):
Coomassie blue stained polyacrylamide gel of the puriﬁed GST-fusion fragments. (Bottom panel) Autoradiography of in vitro phosphorylated Mdc1
fragments. (b) A conserved motif at the very N-terminus of Mdc1 is phosphorylated by ATM in vitro. Top: Sequence alignment of the Mdc1
N-terminus. The highly conserved Thr residue at position 4 (T4) is highlighted by an arrowhead. (Bottom) ATM phosphorylation of fragment M-1
and the mutant T4A. AR, Autoradiograph; CB, Coomassie blue; IB, immunoblot; PS, Ponceau red. (c) (Left panel) Dose titration using the pThr-4
phosphospeciﬁc antibody (pT4). (Right panel) Kinetics experiment using the pT4 phosphospeciﬁc antibody. The band corresponding to Mdc1 is
highlighted by an arrowhead. (d) Mdc1+/+, Mdc1/– MEFs were irradiated with various doses of IR. Extracts were probed with the pT4 antibody. (e)
Mdc1 Thr-4 phosphorylation in response to IR is ATM-dependent. U2OS cells were pre-treated with highly speciﬁc inhibitors of ATM (KPL0064:
Kudos), DNA-PKcs (NU7026: Kudos) or a combination of both. Cell extracts were probed with the phosphospeciﬁc pT4 antibody. (f) Mdc1 is not
phosphorylated in cells derived from an A-T patient. A-T cells and control U2OS cells were irradiated and extracts were probed with the pT4
antibody.
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inhibitor or with a combination of ATM and DNA-PKcs
inhibitors, while the signal was still present, albeit weaker,
when the cells had been pre-treated with the DNA-PKcs
inhibitor alone (Figure 1e). In addition, no Mdc1 signal
was detected by the pT4 antibody in extracts prepared
from irradiated A-T cells (Figure 1f). Together, these
data show that Mdc1 contains a conserved PIKK target
site at its very N-terminus and that, in response to IR, this
is mainly targeted by ATM in vivo.
The phosphorylated N-terminus of Mdc1 binds to its own
FHA domain
To understand the functional implication of Mdc1 Thr-4
phosphorylation, we carefully analyzed the amino acid
sequence surrounding the PIKK target site. Besides the
TQ motif, several additional amino acids are conserved,
most notably an isoleucine three residues C-terminal to
the phosphoacceptor threonine (Figure 1b). This is
intriguing since pT-X-X-I was previously shown to consti-
tute a favored motif for certain classes of FHA domains
(24). Indeed, the entire N-terminal motif (M-E-D-pT-
Q-A-I) resembles that derived for the Mdc1 FHA
domain by oriented library screening in these earlier
studies (Figure 2a). In order to test whether the phos-
phorylated N-terminus of Mdc1 could serve as a binding
site for an FHA domain-containing protein, we designed a
phosphopeptide comprising the ﬁrst 12 N-terminal
residues of human Mdc1 phosphorylated on Thr-4. The
phosphopeptide and its unphosphorylated derivative were
coupled to magnetic beads and used to pull-down proteins
from HeLa nuclear extracts. Both peptides retrieved
several proteins that appeared as clear bands on a SDS–
polyacrylamide gel (Supplementary Figure S5), but at
least three proteins were pulled down by the phos-
phopeptide only, but not by its unphosphorylated coun-
terpart. Most prominent were two bands of 250 kDa
identiﬁed as Mdc1 itself by western blot analysis with an
antibody against human Mdc1 (Figure 2b). The other two
bands at 150 and 80 kDa were RAD50 and MRE11,
respectively. Together with our previous ﬁnding that
Mdc1 exists in a complex with MRN in HeLa nuclear
extracts (8,13), these results indicate that Mdc1 may be
the predominant interaction partner of its own
phosphorylated N-terminus.
Of the two phosphor-speciﬁc protein binding domains
within Mdc1 (Figure 1a), phosphopeptide pull-down ex-
periments with bacterially expressed GST-fusion proteins
of these regions showed that only the FHA domain
bound tightly and speciﬁcally to the Mdc1 N-terminal
phosphopeptide, with no signiﬁcant interaction detectable
for the C-terminal BRCT-repeat region (Figure 2c). Fur-
thermore, we were able to demonstrate high afﬁnity binding
of puriﬁed Mdc1 FHA to a synthetic phosphopeptide en-
compassing the Thr-4 motif by isothermal titration calor-
imetry (ITC) (Figure 2d). Interestingly, these data could
only be satisfactorily ﬁt using a model incorporating two
independent phosphopeptide binding sites (see below).
In order to conﬁrm these interpretations in an unbiased
manner, we performed a SILAC-based screen for inter-
action partners of the Mdc1-FHA domain by mass
spectrometry that is further described later. Importantly,
analysis of protein complexes pulled down by the over-
expressed Mdc1 FHA domain revealed a clear interaction
with endogenous Mdc1 and Mdc1 phosphorylation on
Thr-4 could be unambiguously conﬁrmed (Figure 2e).
Furthermore, Stable Isotope Labelling with Amino-acids
in Cell culture (SILAC) and extracted ion chromato-
gram-based quantitation (25) of the signal abundances
of phosphorylated and unphosphorylated Thr-4 peptides
from a similar SILAC screen reveals an increase in
intensity-dependent occupancy rate for the phospho-
rylated Thr-4 peptide from 18.6% to 61.5% after irradi-
ation. While the unphosphorylated form of the second
possible ATM site, Thr-98, was detected, no phospho-
rylated form was evident (Supplementary Figure S6a).
Signiﬁcantly, Thr-98 occurs within an Asn-Gly-Thr/Val
or ‘NGT’ motif conserved in a majority of FHA
domains. Here, it packs into the protein core and struc-
turally supports the preceding asparagine residue that, in
turn, makes crucial hydrogen-bonding contacts with
main-chain atoms from bound phosphopeptides (ref. 24;
and this paper). Together, these observations have impli-
cations for a recently proposed mechanism of Mdc1 oligo-
merization through FHA binding to pThr-98 (26).
Interestingly, we could not detect peptides for ATM,
Rad51 or Chk2 in the protein fraction pulled down by
the Mdc1–FHA domain, even though these three proteins
have previously been proposed to interact directly with the
Mdc1–FHA domain (3,9,10,12). We were also unable to
detect ATM or Chk2 in these fractions by western blot
analysis (Supplementary Figure S6b) and no interaction of
puriﬁed Mdc1–FHA domain with a phosphopeptide con-
taining ATM pSer-1981 motif by ITC was observable
(Supplementary Figure S6c). This contrasts with previous
observations of this interaction by other methods (10) but
the lack of binding is wholly consistent with a generally
accepted view that FHA domains are pThr speciﬁc.
The Mdc1–FHA domain forms a dimer
In order to characterize the Mdc1–FHA–pThr 4 inter-
actions further, we determined the structures of both
free and phosphopeptide-bound forms at high resolution
by X-ray crystallography. The pThr-4 phosphopeptide
complex structure was solved using the single wavelength
anomalous diffraction method with crystals grown from
selenomethionine-substituted Mdc1–FHA domain, and a
synthetic peptide in which Ala-6 was also replaced by
selenomethionine, an approach we have described previ-
ously (27). The reﬁned coordinates of the complex were
then used to solve the structure of the peptide-free form by
molecular replacement. Data collection and reﬁnement
statistics are shown in Table 1 along with representative
electron density for residues at the edge of the FHA dimer
interface (Figure 3a).
As expected, the Mdc1–FHA domain adopts an
11-stranded b-sandwich fold that is characteristic of
these signaling modules (Supplementary Figure S7).
Strikingly, we observed two FHA domains in the
asymmetric unit in both peptide-free and bound forms,
each similarly arranged around a pseudo 2-fold
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Figure 2. The phosphorylated Mdc1 N-terminus constitutes a recognition motif for the Mdc1–FHA domain. (a) The N-terminal Mdc1 pThr-4
sequence closely resembles the optimal binding motif derived previously (24) by oriented peptide library selection. Circled residues highlight exact
matches. (b) Immunoblot analysis indicates that endogenous Mdc1 is efﬁciently pulled down by the pThr-4 phosphopeptide. (c) Coomassie
blue-stained PAGE of a pThr-4 phosphopeptide pull-down experiment using puriﬁed M-1 GST-fragment (containing the FHA domain) and
puriﬁed M-8 GST-fragment (containing the BRCT domains). (d) Upper panel—ITC binding isotherm for interaction of a phosphorylated (upper)
or non-phosphorylated (lower) synthetic Thr-4 peptide with recombinant Mdc1–FHA domain. Data were analyzed assuming one or two site binding
which consistently favored the latter model, showing tight, stoichiometric (1:1) binding to similar but non-identical sites. (e) Representative MS ion
fragment spectra of the N-terminal Mdc1 tryptic peptide showing phosphorylation at Thr-4 acquired with high mass accuracy (ppm) and a false
discovery rate (PEP) below 1%.
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non-crystallographic symmetry axis (Figure 3b and
Supplementary Figure S8). Although other FHA–FHA
lattice interactions are observed in the two crystal forms,
the non-crystallographic interaction surface is the most
extensive burying a total of 900A˚2/dimer in each case.
Of these, 600A˚2 are contributed by non-polar atoms
from the side-chains of Phe-37, Leu-101, Leu-120,
Leu-122 and Leu-127 (Figure 3c), all highly conserved in
available sequences of Mdc1 orthologs (Figure 3d).
Together these residues form a hydrophobic cluster on
one face of each FHA b-sandwich that is tightly packed
with high surface complementarity at the interface.
In the light of these observations, we examined the
solution behavior of the isolated FHA by size-exclusion
chromatography combined with multi-angle laser light
scattering (SEC-MALLS) that is able to conveniently
measure shape independent and accurate molecular
weights from chromatographic peaks, circumventing
the need for analytical ultracentrifugation analysis.
The molar mass distribution across the chromatographic
peak showed an apparent molecular weight of 18.3
±0.06 kDa, some 40% greater than the calculated
monomer mass of 12.8 kDa unambiguously demon-
strating self-association of the Mdc1–FHA domain
(Figure 3e). Moreover, a double mutation, L120E/
L127E, resulted in a signiﬁcant reduction in apparent
molecular weight (14.3 kDa; Figure 3e) presumably due
to juxtaposition of repulsive charges at the interface.
Thus, we conclude that the dimeric arrangement
observed in the crystal structures is indeed representative
of the dimer we observe in solution.
Thr-4 phosphorylation stabilizes Mdc1–FHA domain
dimerization
The structure of the Mdc1–FHA/phosphopeptide
complex (Figure 4a) shows a binding mode for the
pThr-4 motif resembling that seen in many previously
reported FHA domain complexes (28). The phospho-
threonine is held by a network of hydrogen bonds with
the highly conserved Arg-58 and Ser-72 side-chains along
with accessory interactions with Lys-73 (Figure 4b). Ile-7
occupies the pThr +3 position that has been shown to
represent a major determinant of FHA speciﬁcity (18)
and interacts with the FHA domain through a shallow
pocket. Interestingly, Trp-9 that is present in all avail-
able sequences of Mdc1 orthologs is the last peptide
residue visible in electron density maps and sits in a
cleft formed at the edge of the FHA–FHA interface.
Since the local 2-fold symmetry is imperfect, the FHA
domain interactions of the Trp-9 side-chain from the
non-crystallographic symmetry-related peptide are still
signiﬁcant but less extensive, potentially explaining the
two binding sites apparent in ITC measurements.
Regardless, the structural data strongly suggest that
pThr motif binding might contribute to the overall stabil-
ity of the dimeric complex and further SEC-MALLS
analysis (Figure 4c) clearly showed that addition of the
pThr-4 peptide substantially increases the apparent
weight-averaged molecular weight to within 90% of
that calculated for a fully dimeric, peptide-bound
complex. Consistent with the structural location of
Trp-9 at the FHA–FHA interface, a peptide variant con-
taining a W9A substitution results in no signiﬁcant dimer
stabilization.
These data reveal a dimeric FHA domain architecture
that is stabilized through binding of each FHA domain
in trans to a motif representing the ATM-phosphorylated
Mdc1 N-terminal region. In support of this idea, we
note that the conserved and highly acidic region
(residues 10–18) C-terminal to Thr-4 could potentially
interact with an equally conserved basic patch adjacent
to the pThr-4 binding site but located on the adjacent
protomer of the Mdc1 dimer (Figure 4d). Nonetheless,
we realized that other arrangements are possible when
the N-terminal motif is covalently attached to the
FHA through the intervening linker region (Figure 4e).
In particular, the peptide-binding data did not eliminate
the possibility of polymerization of the intact molecule,
nor did they exclude intra-molecular binding of the
phosphorylated N-terminal motif to its own FHA
domain as we have observed previously for the Rv1827
FHA-domain protein from Mycobacterium tuberculosis
(29). In order to distinguish between these possibilities,
we used expressed protein ligation technology to
generate a speciﬁcally and stoichiometrically Thr-4-
phosphorylated sample (Figure 4f, left panel) as we had
Table 1. Crystallographic statistics
Mdc1/pThr-4
(Se SAD)
Mdc1
Data collection
PDB ID 3UOT 3UN0
Space group P212121 P212121
Cell dimensions (A˚)
a, b, c (A˚) 58.5, 59.9, 72.1 35.3, 54.7, 98.1
Peak
Wavelength (A˚) 0.9790
Resolution (A˚)a 15.0–1.8 (1.86–1.80) 20.0–2.3 (2.40–2.30)
Rmerge (%) 3.7 (31.5) 8.4 (40.4)
<I/s(I)> 27.5 (2.1) 11.7 (2.8)
Completeness (%) 93.4 (55.3) 93.7 (90.2)
Redundancy 3.2 (2.1) 3.0 (2.9)
Reﬁnement
Resolution (A˚) 15–1.8 15.0–2.3
No. of reﬂections 21 805 7988
Rwork/Rfree (%) 20.5/24.3 20.7/26.1
No. of atoms
Protein 1757 1699
Peptide 142 –
Water 150 79
Sulphate – 7
B-factors (A˚2)
Protein 25.4 39.2
Peptide 45.0 –
Water 41.2 50.8
R.m.s deviations
Bond lengths (A˚) 0.01 0.009
Bond angles () 1.5 1.5
Ramachandran plot (%)
Favored 225 (97.4) 199 (94.3)
Allowed 5 (2.2) 10 (4.7)
Disallowed 1 (0.4) 2 (1)
aValues in parentheses are for highest resolution shell.
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done previously for Chk2 (30). SEC-MALLS analysis of
this molecule reported an apparent molecular weight
of 31.2 kDa, essentially identical to the formula mass of
the fully dimeric phosphorylated fragment (31 110Da)
(Figure 4f, right panel). Thus, we conclude that pThr-4
phosphorylation results in tight Mdc1 dimerization
through a head-to-tail mechanism.
Mdc1 self-association occurs in human cells and is
pThr-4-dependent
We next asked whether the head-to-tail dimer also occurs
in human cells. First, we used differentially tagged
Mdc1 fragments to detect homotypic interaction by
co-immunoprecipitation. As shown in Figure 5a, a
Figure 3. Mdc1–FHA domain dimerization. (a) Stereo view of a segment of omit electron density map (1.25s) at the periphery of the FHA–FHA
interface from the 1.8 A˚ resolution peptide complex. Protein residues are shown as stick representation and water molecules are shown as red spheres.
(b) Ribbons representation of the dimeric arrangement observed in the peptide-free Mdc1–FHA crystal structure. The position of the local 2-fold
symmetry axis is indicated. All structural representations were generated using PyMOL (http://pymol.sourceforge.net/). (c) FHA–FHA interactions
are predominantly mediated by a conserved cluster of ﬁve hydrophobic residues from each protomer. (d) Interface residues are highly conserved in all
available sequences of Mdc1 orthologs. The locations of b-strands observed in the structure are indicated in the lower panel, along with the positions
of the four residues most highly conserved in the FHA domain family (circles). (e) SEC-MALLS analysis of the wild-type Mdc1–FHA (27–138) and
a mutant form in which two residues that form the core of the observed dimer interface have been substituted with glutamate. The observed
weight-averaged molecular weight of the mutant is substantially less than the wild-type protein. The shorter retention time for the mutant may reﬂect
a more extended shape for monomeric forms, or differential electrostatic effects on interaction of the mutant with the weakly anionic column matrix.
Thin lines, UV absorbance; thick lines, derived molar mass distributions across the chromatogram peak.
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Flag-tagged Mdc1 fragment (1–800) efﬁciently interacted
with an identical Myc-tagged fragment. An N-terminal
Mdc1 fragment lacking the BRCT domains was used
to avoid avid association of Mdc1 with DNA
damage-induced chromatin. Surprisingly, interaction
between the two fragments was not completely dependent
on IR treatment. However, we noticed that transiently
expressed Mdc1 (1–800) fragment was constitutively
Figure 4. Head-to-tail dimerization is stabilized by pThr-4. (a) Structure of the Mdc1/pThr-4 peptide complex is shown as a Ca plot/surface
representation with the peptide shown as sticks, viewed along the local 2-fold symmetry axis. (b) The phosphopeptide interacts with conserved
FHA domain residues mainly through pThr-4 and main-chain atoms from pT+1 and+3 residues. The Trp-9 indole nestles in a cleft formed at the
interface between the two FHA domains in the dimer. (c) SEC-MALLS analysis shows that a substantial stabilization of the Mdc1–FHA dimer by
the pThr-4 peptide is greatly reduced by substitution of Trp-9 with alanine (W9A). The slight differences in retention times of the peptide-free
wild-type FHA observed in this experiment and that of Figure 3c arise from small differences in the on-column concentration (typically ±3–4%), the
weak self-association of the unphosphorylated molecule and the fact that peak concentrations are of the same order as the estimated dimerization
afﬁnity. (d) The sequence C-terminal to the pThr-4 motif (yellow) contains a highly conserved stretch of acidic residues highlighted in blue (top
panel). These would be predicted to interact with arginine and lysine residues that are also conserved and form a basic patch adjacent to the binding
site for the peptide C-terminus of the bound peptide (bottom). (e) Cartoon showing the three most likely effects of Thr-4 phosphorylation.
(f) Ligation of an extended pThr-4 peptide to trypsin-cleaved Mdc1–FHA (left) produces a stoichiometrically and speciﬁcally phosphorylated
protein encompassing the entire N-terminal region that forms a tight dimer by SEC-MALLS analysis (right). Mo, observed molecular weight;
Mc, calculated molecular weight.
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Figure 5. Dimerization of the Mdc1 N-terminal region in vivo. (a) The interaction between differentially tagged Mdc1 N-terminal fragments is
dependent upon the intact FHA domain and Thr4 phosphorylation. 293T cells were transiently transfected with Flag-tagged Mdc1 (1–800 amino
acids) and Myc-tagged Mdc1 (1–800 amino acids) wild-type and the indicated mutants, respectively. Protein complexes were immunoprecipitated
with monoclonal anti-Flag agarose and immunoblotted with polyclonal anti-Myc and polyclonal anti-Flag antibodies. (b) The Mdc1–FHA domain is
recruited to damaged chromatin regions. U2OS expressing a tetracycline-inducible EYFP–FHA (WT)TetOn fusion protein were treated with
doxocyclin for 1 h and subjected to laser irradiation. Cells were ﬁxed 30min after irradiation and immunostained for gH2AX. (c) Kinetics of
Mdc1–FHA domain recruitment. U2OS FHA (WT)-EYFPTetOn cells were incubated with doxocycline for 1 h and subjected to laser irradiation.
Time lapse live cell microscopy was performed and images were taken at the indicated times. Note that for technical reasons, 0min time point was
taken about 20 sec after microirradiation. (d) Recruitment of Mdc1–FHA domain is dependent on endogenous Mdc1. U2OS FHA(WT)EYFPTetOn
cells were either treated with control siRNA or siRNA against endogenous Mdc1. Cells were induced with doxocycline for 1 h, subjected to laser
irradiation and images were taken 30min thereafter. Cells were subsequently ﬁxed and immunostained for gH2AX. (e) Recruitment of Mdc1–FHA
domain is dependent on phospho-speciﬁc interaction between Thr4 and the FHA domain as well as on an intact hydrophobic interface between FHA
monomers. U2OS FHA-EYFPTetOn cells expressing the wild-type and indicated mutants were induced with doxocyclin for 1 h, subjected to laser
irradiation and images were taken 30min thereafter. Cells were subsequently ﬁxed and immunostained for gH2AX.
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phosphorylated on Thr-4 even without prior irradiation of
the transfected cells (data not shown). Since Thr-4 phos-
phorylation of endogenous Mdc1 is clearly DNA damage
dependent (Figure 1), we assume that this effect is a result
of the transfection procedure (31). Nevertheless, a
moderate increase in the interaction could be detected
upon treatment of cells with IR (Supplementary
Figure S9a). In addition, the Mdc1 (1–800) frag-
ment co-immunoprecipitated with endogenous Mdc1 ex-
clusively in extracts prepared from IR-treated cells
(Supplementary Figure S9b). Crucially, mutation of
either the FHA domain (R58A) or a T4A substitution
led to a signiﬁcant reduction of the interaction between
Flag-tagged and Myc-tagged Mdc1 (1–800) and concomi-
tant mutation of both the FHA domain and Thr-4
resulted in a complete loss of binding (Figure 5a). To
eliminate the possibility that one or both of the other
two classes of known pThr-containing phosphorylation
sites within Mdc1—pSDpTD (13,32–34) and pTQxF
(21,23)—were contributing to interactions of the Mdc1
(1–800) FHA domain we carried out ITC titrations of
the recombinant Mdc1–FHA with synthetic versions of
these phosphomotifs. No detectable interactions were
observable in either case (Supplementary Figure S10).
On the basis of these experiments, we reasoned that if
DNA damage-induced Mdc1 dimerization occurs via the
FHA domain, we should detect partial recruitment of the
FHA domain to sites of DSBs through association with
endogenous Mdc1. Moreover, this recruitment should be
diminished by mutations in either the FHA domain or at
the pThr-4 site. To circumvent limitations of the static
assessment of IRIF formation in ﬁxed cells, we used an
integrated imaging unit that combines microlaser-assisted
generation of spatially deﬁned DSB areas in mammalian
cells with rapid, continuous and interactive image acqui-
sition (35,36). Since it has been previously observed that
overexpression of the Mdc1–FHA domain interferes with
accumulation of DDR proteins (including Mdc1 and the
Mre11/Rad50/Nbs1 complex) at sites of DSBs (5,11,37),
we also generated a panel of cell lines derived from
checkpoint-proﬁcient U2OS cells carrying stably inte-
grated, tetracycline-regulated expression cassettes direct-
ing the expression of the Mdc1–FHA domain fused to
enhanced yellow ﬂuorescent protein (EYFP). Signiﬁ-
cantly, when expressed at low levels, the Mdc1–FHA
domain is recruited to microlaser-induced DNA damage
(Figure 5b). The real-time measurements revealed a
rapid accumulation of the fusion protein around the
laser generated, DSB-containing, subnuclear tracts
(Figure 5c), with a detectable increase in ﬂuorescence
in the damaged nuclear compartments within 20–30 s
(Figure 5c, ﬁrst panel). Subsequently, the fusion protein
underwent a rapid accumulation in the DSB regions, and
reached a steady-state by 8–10min after laser exposure.
Importantly, no increase in ﬂuorescence was observed in
DSB-containing laser tracks in Mdc1-depleted cells,
indicating that EYFP–FHA domain accumulation is
strictly dependent on endogenous Mdc1 (Figure 5d).
Moreover, no accumulation was detectable in cells that
express T4A or the R58A and L120/127E mutant deriva-
tives of the FHA domain (Figure 5e). Thus, these data
reveal that FHA accumulation to microlaser-induced
DNA damage in living human cells mirrors the in vitro
requirements for Mdc1 dimerization, strongly supporting
the notion that Mdc1 dimerization in response to DNA
damage also occurs in vivo and that is does so in a manner
that is consonant with our structural data.
Mdc1 dimerization does not inﬂuence Mdc1 recruitment
or 53BP1 localization to sites of DNA double-strand
breaks
It was previously demonstrated that overexpression of
the Mdc1–FHA domain yields a dominant-negative
impact upon Mdc1 accumulation at sites of DNA
damage (5,37,38). Thus, we sought to investigate
whether FHA-mediated Mdc1 dimerization was required
for optimal recruitment of full-length Mdc1 to sites of
DNA damage. To this end, we generated stable U2OS
cell lines expressing GFP-tagged versions of full-length
wild-type Mdc1 or T4A mutant Mdc1 (Supplementary
Figure S11). Both quantitative real-time imaging on
microlaser-induced DNA damage tracks in living cells
(Supplementary Figure S12a) as well as immunoﬂuores-
cence analysis on IR-treated ﬁxed cells (Supplementary
Figure S13) revealed that the T4A mutation had no inﬂu-
ence on full-length Mdc1 recruitment to sites of DSBs.
Since it has also been recently suggested that DNA
damage-induced Mdc1 oligomerization, presumably
through the mechanism that we describe, is required for
53BP1 accumulation at sites of DNA damage (39) we also
analyzed the effect of the Mdc1 T4A mutation on 53BP1
foci formation. We transiently transfected Mdc1/
mouse embryonic ﬁbroblasts with full-length HA-tagged
mouse Mdc1 (wild-type or T4A mutant) and assessed
53BP1 foci formation after irradiation by immunoﬂuores-
cence. Even though a subtle (but reproducible) reduction
of the number of cells with 53BP1 foci was detectable in
the T4A-expressing cells as compared to wild-type-
expressing cells (Supplementary Figure S12b), 53BP1
foci formation appeared to be relatively normal in
most reconstituted Mdc1/ MEFs, suggesting that
FHA-mediated Mdc1 dimerization is not essential for
53BP1 accumulation, although it may contribute to its
regulation.
A screen for interaction partners of the Mdc1–FHA
domain
Finally, in order to directly investigate Mdc1–FHA inter-
actions in human cells, we designed an unbiased and quan-
titative proteomic analysis of Mdc1–FHA interaction
partners in the presence and absence of DNA damage.
SILAC-labeled U2OS cells stably expressing an empty
control plasmid or a Strep-tagged Mdc1–FHA domain
(amino acids 1–154) were irradiated with 10Gy of IR or
left untreated. FHA-interacting proteins were then pulled
down by Strep-Tactin Sepharose and eluted from the
beads. The eluates were combined, digested with trypsin
and analyzed by high-resolution LC–MS/MS (Figure 6a).
The Mdc1–FHA interaction ‘afﬁnities’ were determined
by a quantitative comparison of tryptic peptide abun-
dances (Figure 6b). Each tryptic peptide occurred as a
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SILAC triplet. If the SILAC peptide intensity ratio
between light, medium and heavy peaks is 1:1:1 the
identiﬁed protein was considered a background binder
(Scenario I). Proteins signiﬁcantly enriched in heavy
isotope encoded samples show high SILAC ratios, and
hence were considered Mdc1–FHA-speciﬁc interaction
partners (Scenario II). Proteins enriched in IR-treated
SILAC state were regarded as damage-speciﬁc FHA inter-
action partners (Scenario III), while proteins only
enriched in untreated SILAC state were regarded as
damage-speciﬁc dissociating proteins (Scenario IV).
As expected, the data revealed that Thr-4 phosphoryl-
ation of the Mdc1–FHA fragment used as bait in
this screen increased substantially upon IR treatment
(Figure 2e). Moreover, quantitative comparison of
tryptic peptide abundances revealed endogenous Mdc1
as a DNA damage-speciﬁc interaction partner of its own
FHA domain as predicted from our biochemical,
Figure 6. SILAC analysis FHA-dependent interactions of Mdc1. (a) Experimental scheme of the quantitative analysis of MDC1–FHA domain
interaction partners. (b) Schematic representation of the interpretation of quantitative SILAC data. (c) DNA damage-dependent interaction partners
of the MDC1–FHA domain. (Left) Survey full scan MS spectrum of an MDC1 peptide showing a SILAC ratio, which corresponds to a
damage-increased interaction with the MDC1–FHA domain whereas the SILAC ratio of a DCAF1 peptide shows a ratio indicating a
damage-speciﬁc dissociation. (Right) Normalized log2 SILAC ratios (IR/+IR; 10Gy, 30min) for MDC1, DDB1 and DCAF1 as quantiﬁed by
the mass spectrometric MDC1–FHA pull-down experiment. (d) Experimental scheme of the quantitative analysis of MDC1–FHA domain interaction
partners in response to IR using over expressed MDC1–FHA WT and T4A mutant domains. (e) Dimerization-dependent interaction partners of the
MDC1–FHA domain. Normalized log2 SILAC ratios (WT+IR/T4A+IR; 10Gy, 30min) for MDC1 and RNF95 as quantiﬁed by the mass spec-
trometric MDC1–FHA pull-down experiment.
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structural and cell-biological data. Interestingly, DDB1
(DNA damage binding protein 1) and DCAF1 (DDB1-
and Cul4-associated factor 1), two proteins that occur in a
Cul4-dependent ubiquitin ligase complex showed a signiﬁ-
cant (>2.5-fold) decreased interaction with the MDC1–
FHA domain in the presence of DNA damage, thus sug-
gesting that the Cul4/DDB1/DCAF1 complex may dis-
sociate from MDC1 upon induction of DNA damage
(Figure 6c).
Finally, a further screen to investigate IR-speciﬁc inter-
actions indicated by the initial wild-type FHA analysis
was carried out using plasmid only control cells alongside
IR-treated cells expressing either wild-type or T4A mutant
FHA domain (Figure 6d). As expected, endogenous Mdc1
interacts with the wild-type fragment consistent with sta-
bilization of binding by head-to-tail dimerization.
However, these data additionally showed that interactions
with an uncharacterized RING-ﬁnger domain protein,
RNF95, were also signiﬁcantly increased in the wild-
type compared to T4A FHA domain expressing cells
(Figure 6e) suggesting FHA domain dimer-speciﬁc
binding.
DISCUSSION
Mediator proteins perform a variety of crucial roles in
many, if not all aspects of the response to DNA
damage. Although these molecules are essentially unre-
lated, oligomerisation now appears to be core feature
of their activities and 53BP1, along with budding yeast
Rad9 and ﬁssion yeast Crb2 have all been shown
to self-associate albeit through different mechanisms
(40–45). Here, we have presented a comprehensive mo-
lecular description of a novel, FHA-mediated dimeriza-
tion mechanism used by archetypal mediator Mdc1 in
response to ATM phosphorylation following DNA
damage.
A general role for dimerization in FHA domain signaling
Our observation of phospho-independent FHA dimeriza-
tion is intriguing. Previous sequence comparisons have
identiﬁed a patch of low-level conservation associated
with b-strands 9 and 10 and the connecting loop of a
subset of FHA domains, leading to the suggestion that
this may act as a self-interaction surface (46). Our struc-
ture now shows that this putative surface substantially
overlaps with the Mdc1 dimer-forming region
(Supplementary Figure S14) and we also show that muta-
tions within this region disrupt FHA–FHA interactions
in vitro (Figure 3d) and in living human cells
(Figure 5e). These and our previous data (29), support a
more expansive role for the b-sandwich architecture in
FHA-mediated interactions than has previously been
envisaged.
Mdc1-like dimerization in Chk2/Rad53 family kinase
activation
Previous studies have suggested that ATM-phospho-
rylated (pThr-68) Chk2 kinase constitutes a pre-activated,
dimeric state (30,47) in which the pThr-68 motif of each
protomer binds to the FHA domain of the other, bringing
the kinase domains together for T-loop phosphorylation
in trans. Indeed, X-ray structures of un-phosphorylated
FHA/kinase domain-containing versions of Chk2 (48)
show that the weak self-association of the isolated
Chk2 FHA domain (30) occurs through interactions that
are closely related to those seen in our Mdc1 structure in
spite of substantial divergence at the sequence level
(Supplementary Figure S15a). We further note that
the two FHA domains that comprise the asymmetric
unit of our earlier crystal structure of an FHA–
phosphopeptide complex from the Chk2 ortholog,
Rad53 (24) (PDB: 1G6G), show an almost identical
dimeric interaction, strongly suggesting that the activation
mechanism of human Chk2 is conserved in all eukaryotes
(Supplementary Figure S15b).
Mdc1 forms a super-scaffold after DNA damage
From a macroscopic viewpoint, a major effect of Mdc1
Thr-4 phosphorylation is to stabilize formation of a ap-
proximately 4000 residue dimeric ‘super-scaffold’ contain-
ing two FHA domains and two BRCT-repeat modules.
Although the major means by which broken DNA ends
are maintained in proximity for efﬁcient repair is through
the bridging function of the MRN complex (49), it may be
that Mdc1 dimers play a contributing role in stabilizing
more global structure within chromatin loops containing
damage sites (50–52) (Figure 7a, left). Such a ‘velcro’
model may also participate in an overall modulation of
local chromatin compaction. Moreover, the existence of
two BRCT-repeat domains within the Mdc1 dimer, and
the signiﬁcant effects of Mdc1 loss on fertility and sperm-
atogenesis (9) may be indicative of a bridging role in
meiotic crossover events. More recently, a model has
been proposed in which Mdc1 self-association permits
multiple C-terminal BRCT-repeat interactions that, sim-
ultaneously, tether Mdc1 to damaged chromatin via inter-
action with gH2AX and recruit phosphorylated forms
of the putative histone H4-K20 methyltransferase,
MMSET (39) (Figure 7a, right). Although our data
show only small effects of Mdc1 dimer disruption on
53BP1 recruitment, this mechanism may still be of rele-
vance for Mdc1 coupling to other proposed BRCT
domain interactors (53).
Dimerization as a direct regulator of Mdc1–FHA
interactions
Mdc1 appears to be the major interacting partner of its
own FHA domain and we have presented a substantial
body of evidence that this self-interaction is mediated by
head-to-tail binding of pThr-4 within the N-terminal
region, with the canonical FHA domain phospho-binding
site. Our proteomic data show that FHA domain inter-
actions with at least a subset of putative cellular partners
are both negatively (DCAF1/DDB1) and positively
(RNF95) impacted by ATM-dependent dimerization.
Although somewhat unexpected, these observations are
entirely consistent with our structural and biochemical
data (Figure 7b). Firstly, pThr-4-mediated dimerization
would be expected to occlude the canonical FHA
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domain phospho-binding surface (Type I) and/or the
FHA–FHA interfacial region that could function as a
phospho-independent binding surface prior to Thr-4 phos-
phorylation (Type II) and which acts in just this way in
other FHA signaling systems (29): either mechanism could
account for the interaction behavior of DCAF1/DDB1.
Secondly, we surmise that Mdc1 dimerization might
create new composite phospho-independent interaction
surfaces spanning both FHA domains (Type III) and
our SILAC analysis comparing binding ratios of
wild-type and T4A mutant FHA domains suggest that
binding to RNF95 might be regulated in this way.
Indeed, an extensive, negatively charged surface
spanning both FHA domains is evident in our crystal
structures (Supplementary Figure S16). Thus, our data
suggest a FHA interaction cycle that is potentially able
to monitor and respond to each stage of the DDR, recruit-
ing and/or releasing accessory repair and signaling factors
in response to ATM and phosphatase activity.
CONCLUDING REMARKS
The fundamental importance of post-translational modi-
ﬁcations, particularly serine/threonine phosphorylation, in
DNA damage-dependent checkpoint establishment and
the assembly of repair and signaling complexes is well
established and Mdc1 has emerged as a focal point for
many of these processes. Our data now reveal an unsus-
pected mode of Mdc1 regulation through ATM-
dependent dimerization through its FHA domain and
show how this phenomenon contributes to Mdc1
function through the damage repair cycle. Overall, our
observations consolidate and extend the emerging signiﬁ-
cance of mediator self-association and provide the ﬁrst
insights into how this occurs at the structural level.
In more general terms, our data reveal mechanisms
for both positive and negative regulation of FHA
domain interactions with phosphorylated and/or non-
phosphorylated partners that will inform future studies
of the myriad signaling pathways beyond the DDR that
employ these versatile interaction modules.
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